From the Journals

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

Share

  • 1

    Study analyzed the impact of SGLT-2 inhibitors on patients with T2D and cirrhosis.

  • 2

    Included 24,259 patients, comparing outcomes with DPP-4 inhibitors.

  • 3

    Found reduced risks of kidney, cardiovascular, and hepatic complications.

  • 4

    Treatment led to lower cases of end-stage kidney disease and acute kidney injury.

  • 5

    Researchers highlighted limitations like lack of lab data on cirrhosis severity.

Original Source(s)

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

  • by Henry Thomas

  • March 10, 2026

  • 2 min

Related Content

What Does Corporate Compliance Really Mean?

Corporate compliance isn’t just about avoiding fines; it’s an opportunity to shape culture, partnerships, and everyday decision-making

Mapping the Metabolism of Plant Mixtures 

A multilayer networking workflow reveals mixture-dependent metabolism of kratom alkaloids A multilayer networking workflow reveals mixture-dependent metabolism of kratom alkaloids 

  • March 10, 2026

  • 3 min
Diabetes Risk Assessment: A New Approach

Blood-based epigenetic markers show strong prognostic potential for Type 2 diabetes